Constellation Pharmaceuticals Revenue and Competitors
Estimated Revenue & Valuation
- Constellation Pharmaceuticals's estimated annual revenue is currently $6.2M per year.
- Constellation Pharmaceuticals received $100.0M in venture funding in April 2018.
- Constellation Pharmaceuticals's estimated revenue per employee is $100,500
- Constellation Pharmaceuticals's total funding is $496.2M.
Employee Data
- Constellation Pharmaceuticals has 62 Employees.
- Constellation Pharmaceuticals grew their employee count by -13% last year.
Constellation Pharmaceuticals's People
| Name | Title | Email/Phone |
|---|---|---|
1 | SVP, Head CMC | Reveal Email/Phone |
2 | VP CMC | Reveal Email/Phone |
3 | Senior Director | Reveal Email/Phone |
4 | Associate Director, Clinical Supply Chain | Reveal Email/Phone |
5 | Global Program Medical Director | Reveal Email/Phone |
6 | Director Computational Biology | Reveal Email/Phone |
7 | Associate Director, Clinical Development | Reveal Email/Phone |
8 | Associate Director Global Patient Safety | Reveal Email/Phone |
9 | Director, Global Patient Safety Product Leader | Reveal Email/Phone |
10 | Associate Director | Reveal Email/Phone |
Constellation Pharmaceuticals Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $413.3M | 324 | 0% | $634M | N/A |
#2 | $47.8M | 238 | 0% | N/A | N/A |
#3 | $2.4M | 12 | -52% | N/A | N/A |
#4 | $25.7M | 128 | 39% | N/A | N/A |
#5 | $12.9M | 64 | 129% | N/A | N/A |
#6 | $23.9M | 119 | 8% | $113M | N/A |
#7 | $0.3M | 3 | 0% | N/A | N/A |
#8 | $10.3M | 51 | -14% | N/A | N/A |
#9 | $1.8M | 367 | -4% | $538M | N/A |
#10 | $50M | 249 | 3% | N/A | N/A |
What Is Constellation Pharmaceuticals?
Constellation Pharmaceuticals is a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics that address serious unmet medical needs in patients with cancers associated with abnormal gene expression. Our integrated epigenetics platform enables us to validate targets and generate small molecules against these targets that selectively modulate gene expression in tumor and immune cells to drive anti-tumor activity. We are able to target a broad variety of epigenetic regulators using our platform and have generated development candidates acting against distinct classes of those regulators.
keywords:Biotechnology,Healthcare,Pharmaceuticals
$496.2M
Total Funding
62
Number of Employees
$6.2M
Revenue (est)
-13%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Constellation Pharmaceuticals News
Honoraria: Research to Practice, Astellas Pharma, AstraZeneca, AstraZeneca ... Sanofi, AstraZeneca, Dendreon, Constellation Pharmaceuticals,...
Prior to his role at Triana, Trojer served as chief scientific officer of Constellation Pharmaceuticals. As CEO, Trojer takes a seat on the...
Trojer previously served as CSO of Constellation Pharmaceuticals. In addition to Dr. Trojer, the leadership team includes CTO and co-founder Dr.
MorphoSys to Acquire Constellation Pharmaceuticals Accelerates Growth Strategy by Adding Two Mid- to Late-Stage Product Candidates: Pelabresib (CPI-0610) and CPI-0209 Bolsters Position in Hematology-Oncology and Expands into Solid Tumors Best-in-Class Combined Discovery and Development Capab ...
Other Companies in Cambridge
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $8.4M | 62 | 2% | N/A |
#2 | $9.6M | 62 | 11% | N/A |
#3 | $18M | 62 | -3% | N/A |
#4 | $11.7M | 62 | 38% | N/A |
#5 | $3.5M | 62 | 22% | N/A |
Constellation Pharmaceuticals Funding
| Date | Amount | Round | Lead Investors | Reference |
|---|---|---|---|---|
| 2008-04-30 | $32.0M | A | Third Rock Ventures, The Column Group | Article |
| 2010-06-04 | $22.0M | B | SR One | Article |
| 2011-06-07 | $15.0M | B | Multiple | Article |
| 2014-08-07 | $5.0M | Undisclosed | Multiple | Article |
| 2015-12-11 | $55.0M | Undisclosed | Article | |
| 2018-04-10 | $100.0M | Undisclosed | Multiple | Article |